Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about LILLY DRN
Recent news which mentions LILLY DRN
< Previous
1
2
3
Next >
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
June 25, 2025
Tags
Biotech and Pharmaceuticals
Health care industry
Social issues
From
CNBC.com News
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
June 17, 2025
Tags
Biotechnology
Companies
Merck & Co Inc
From
CNBC.com News
Cramer's Lightning Round: Eli Lilly is a buy
May 23, 2025
Tags
Business
Investment Strategy
Mr Cooper Group Inc
From
CNBC.com News
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
May 21, 2025
Tags
Business
Pharmaceuticals
Health Insurance
From
CNBC.com News
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
May 19, 2025
Tags
Companies
Biotechnology
Health & Science
From
CNBC.com News
Why Americans pay so much more for prescription drugs
May 14, 2025
Tags
LILLY DRN
Pharmaceuticals
Drug Retail
From
CNBC.com News
Germany's business leaders have a message for the country's new government: It's time to deliver
May 13, 2025
Tags
Europe News
World Politics
Europe Politics
From
CNBC.com News
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
May 12, 2025
Tags
Business
Pharmaceuticals
Merck & Co Inc
From
CNBC.com News
Trump to sign order to cut some U.S. drug prices to match those abroad
May 12, 2025
Tags
LILLY DRN
Breaking News: Business
Business News
From
CNBC.com News
Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
May 07, 2025
Tags
Healthy Returns
CVS Health Corp
LILLY DRN
From
CNBC.com News
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
May 07, 2025
Tags
Biotechnology
Biotech and Pharmaceuticals
AstraZeneca PLC
From
CNBC.com News
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
May 05, 2025
Tags
Health & Science
Abbvie Inc
Business News
From
CNBC.com News
Cramer's week ahead: Earnings from Disney, Palantir and Uber
May 02, 2025
Tags
stocks
Novo Nordisk A/S
ServiceNow Inc
From
CNBC.com News
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
May 02, 2025
Tags
Mergers
Roche Holding AG
LILLY DRN
From
CNBC.com News
Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
May 01, 2025
Tags
Biotechnology
Companies
Biotech and Pharmaceuticals
From
CNBC.com News
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
May 01, 2025
Tags
Breaking News: Business
Business
LILLY DRN
From
CNBC.com News
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
May 01, 2025
Tags
Pharmaceuticals
Business
Biotech and Pharmaceuticals
From
CNBC.com News
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
April 30, 2025
Tags
Abbott Laboratories
GSK plc
LILLY DRN
From
CNBC.com News
Novartis posts better-than-expected first-quarter sales, raises full-year guidance
April 29, 2025
Tags
Pharmaceuticals
Trade
Business
From
CNBC.com News
5 things to know before the stock market opens Monday
April 28, 2025
Tags
Business
5 Things to Know
Economy
From
CNBC.com News
Cramer's week ahead: Key economic data and earnings from Apple, Amazon, Meta and Microsoft
April 25, 2025
Tags
Amazon/com Inc
Exxon Mobil Corp
Apple Inc
From
CNBC.com News
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
April 25, 2025
Tags
Breaking News: Business
LILLY DRN
Health & Science
From
CNBC.com News
Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
April 23, 2025
Tags
Markets
Coinbase Global Inc
Hyundai Motor Co
From
CNBC.com News
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
April 23, 2025
Tags
LILLY DRN
Business
Health & Science
From
CNBC.com News
Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
April 17, 2025
Tags
Pharmaceuticals
Business
Roche Holding AG
From
CNBC.com News
Healthy Returns: What drugmakers are saying about Trump’s looming pharmaceutical tariffs
April 16, 2025
Tags
Healthy Returns
LILLY DRN
Dexcom Inc
From
CNBC.com News
Pfizer scraps daily weight loss pill after liver injury in one patient
April 14, 2025
Tags
Health & Science
Pfizer Inc
Novo Nordisk A/S
From
CNBC.com News
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
April 11, 2025
Tags
Breaking News: Business
Business
LILLY DRN
From
CNBC.com News
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly’
April 09, 2025
Tags
Health & Science
Biotech and Pharmaceuticals
Health care industry
From
CNBC.com News
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
April 09, 2025
Tags
Biotechnology
AstraZeneca PLC
Pharmaceuticals
From
CNBC.com News
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.